For Healthcare Private Equity
IC-grade clinical, regulatory, and manufacturing diligence on each target — and continuous, portfolio-wide monitoring after close. Our flagship Annual Portfolio License (from $150,000/yr) covers ongoing evaluation and post-close tracking; per-deal Quick Screen, Diligence Report, and scoped Transaction Diligence are the entry points. Every material claim cited to a public source — never fabricated.
Batch Pipeline Screening
Watch Vantage transform an unscored pipeline into ranked, actionable intelligence
| Company | Score | Status |
|---|
Competitive Advantage
Dramatically faster and more affordable than a traditional analyst engagement — and fully quantitative.
What We Find
Six headline categories within our 20-category diligence framework.
Clinical adoption as primary risk
Single-source supplier risk
Write-down risk when reimbursement is unvalidated
Differentiator analysis with effect-size disclosure
Will physicians change workflow? We assess adoption barriers invisible to financial DD.
Design-for-manufacturing gaps and supplier integration risks remain invisible until scale-up.
Predicate strategies that won't survive FDA scrutiny. Typical remediation: 12-18 months + $1-3M.
Devices with unclear payer pathways fail post-FDA approval. We map pricing viability.
Cross-category pattern intelligence benchmarked against 800+ outcome-labeled biomedical companies in our proprietary cohort substrate, growing with every engagement.
Single-payer reliance = existential risk. We model coverage change impact.
Pricing
Per-deal evaluations are the entry point; our flagship Annual Portfolio License (from $150,000/yr) delivers portfolio-wide monitoring and post-close tracking — with physician-engineer diligence at every stage.
Typical PE workflow: Most PE clients enter with a per-deal evaluation — a Quick Screen or Diligence Report to validate target fit and quantify clinical risk — then move to our flagship Annual Portfolio License (from $150,000/yr) for portfolio-wide monitoring, post-close tracking, and IC-grade diligence on demand. For a full platform or bolt-on acquisition, Transaction Diligence is scoped and priced to deal complexity (from $100,000). Contact us for a scoped proposal.
Flagship: Annual Portfolio License / Monitoring from $150,000/yr — portfolio-wide coverage with post-close surveillance included. Per-deal: Quick Screen $5,000 · Diligence Report $15,000 · Transaction Diligence from $100,000, scoped to the deal.
Companies that skip clinical-technical due diligence carry materially higher write-down risk when clinical, manufacturing, and reimbursement gaps surface only after close.
Deal Integration
Risk intelligence from deal sourcing through post-close monitoring
Portfolio screening to identify clinical and manufacturing risks early
Rapid triage on target profile and strategic fit
Full assessment with IC-ready report and questions
Board-ready presentation with risk quantification
Integration checkpoints and portfolio risk tracking
How we'd diligence a platform
Each card is a public retrospective, not a private case. The point is to show the framework: what we'd score, what we'd flag, and what an LP would have seen pre-deal.
Polyethylene packaging defect, 200K+ implants recalled, 2024 Chapter 11. Walks the manufacturing-control and complaint-trend signals a platform DD would have caught.
Read the retrospective →FDA warning letter forced a category change post-IPO, halting US sales for 18 months. The classification risk was knowable from public filings predating the deal.
Read the retrospective →First FDA-cleared prescription digital therapeutic, $1.6B SPAC, bankruptcy in 24 months. Traces the payer-coverage and prescribing-economics signals available at deal time.
Read the retrospective →Transaction Diligence is scoped per deal (from $100,000) — confidentiality precludes named client work until a sponsor authorizes attribution.
Portfolio-wide monitoring, post-close tracking, and IC-grade diligence on demand — from $150,000/year — for active platform investors. Continuous coverage across your platform and add-ons, with every material claim cited to a public source and independent of banker- or target-supplied materials, drawn from our proprietary multi-source substrate.
Talk to Arvind, MD →Enter per deal with a Quick Screen or Diligence Report, or talk to Arvind about our flagship Annual Portfolio License for portfolio-wide monitoring and post-close tracking.
The 15 regulatory, clinical, and commercial red flags that kill healthcare deals — written by Arvind Ravinutala, MD and Aswini Ravinutala, BME.
Download the GuideNo email required. No paywall.